Use of a Physiologically Based Pharmacokinetic Model to Study the Time to Reach Brain Equilibrium: An Experimental Analysis of the Role of Blood-Brain Barrier Permeability, Plasma Protein Binding, and Brain Tissue Binding

This study was designed 1) to examine the effects of blood-brain barrier (BBB) permeability [quantified as permeability-surface area product (PS)], unbound fraction in plasma (fu,plasma), and brain tissue (fu,brain) on the time to reach equilibrium between brain and plasma and 2) to investigate the drug discovery strategies to design and select compounds that can rapidly penetrate the BBB and distribute to the site of action. The pharmacokinetics of seven model compounds: caffeine, CP-141938 [methoxy-3-[(2-phenyl-piperadinyl-3-amino)-methyl]-phenyl-N-methyl-methane-sulfonamide], fluoxetine, NFPS [N[3-(4′-fluorophenyl)-3-(4′-phenylphenoxy)propyl]sarcosine], propranolol, theobromine, and theophylline in rat brain and plasma after subcutaneous administration were studied. The in vivo log PS and log fu,brain calculated using a physiologically based pharmacokinetic model correlates with in situ log PS (R2 = 0.83) and in vitro log fu,brain (R2 = 0.69), where the in situ PS and in vitro fu,brain was determined using in situ brain perfusion and equilibrium dialysis using brain homogenate, respectively. The time to achieve brain equilibrium can be quantitated with a proposed parameter, intrinsic brain equilibrium half-life [t1/2eq,in = Vbln2/(PS · fu,brain)], where Vb is the physiological volume of brain. The in vivo log t1/2eq,in does not correlate with in situ log PS (R2 < 0.01) but correlates inversely with log(PS · fu,brain) (R2 = 0.85). The present study demonstrates that rapid brain equilibration requires a combination of high BBB permeability and low brain tissue binding. A high BBB permeability alone cannot guarantee a rapid equilibration. The strategy to select compounds with rapid brain equilibration in drug discovery should identify compounds with high BBB permeability and low nonspecific binding in brain tissue.

[1]  R. M. Lightfoot,et al.  Use of Ca2+ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes. , 1999, The Journal of pharmacology and experimental therapeutics.

[2]  T. Maurer,et al.  RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE , 2005, Drug Metabolism and Disposition.

[3]  M. Yamazaki,et al.  Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.

[4]  R. FitzHugh,et al.  Drug entry into and distribution within brain and cerebrospinal fluid: [14C]urea pharmacokinetics. , 1982, The American journal of physiology.

[5]  W. Jusko,et al.  Effects of obesity and ancillary variables (dialysis time, drug, albumin, and fatty acid concentrations) on theophylline serum protein binding. , 1989, Biopharmaceutics & drug disposition.

[6]  J. Besterman,et al.  Macrophage phagocytosis: analysis of particle binding and internalization. , 1982, The American journal of physiology.

[7]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[8]  M. Bonati,et al.  Kinetics and metabolism of theobromine in male rats. , 1984, Toxicology.

[9]  Xi Chen,et al.  THE IMPACT OF P-GLYCOPROTEIN ON THE DISPOSITION OF DRUGS TARGETED FOR INDICATIONS OF THE CENTRAL NERVOUS SYSTEM: EVALUATION USING THE MDR1A/1B KNOCKOUT MOUSE MODEL , 2005, Drug Metabolism and Disposition.

[10]  S. Garattini,et al.  Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat , 2005, Psychopharmacology.

[11]  C S Patlak,et al.  A method to obtain infusion schedules for prescribed blood concentration time courses. , 1976, Journal of applied physiology.

[12]  M Rowland,et al.  Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. , 2001, Antisense & nucleic acid drug development.

[13]  G. M. Pollack,et al.  Altered disposition and antinociception of [D-penicillamine(2,5)] enkephalin in mdr1a-gene-deficient mice. , 1998, The Journal of pharmacology and experimental therapeutics.

[14]  L. Chauvelot‐Moachon,et al.  Alpha-1-acid glycoprotein concentrations and protein binding of propranolol in Sprague-Dawley and Dark Agouti rat strains treated by phenobarbital. , 1988, The Journal of pharmacology and experimental therapeutics.

[15]  Xingrong Liu,et al.  Utility of Mdr1-gene deficient mice in assessing the impact of P-glycoprotein on pharmacokinetics and pharmacodynamics in drug discovery and development. , 2003, Current drug metabolism.

[16]  S. Kajiji,et al.  P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists. , 2001, The Journal of pharmacology and experimental therapeutics.

[17]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[18]  L. Paalzow,et al.  Drug Equilibration Across the Blood—Brain Barrier-Pharmacokinetic Considerations Based on the Microdialysis Method , 1997, Pharmaceutical Research.

[19]  S. Khor,et al.  Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[20]  R. Sawchuk,et al.  Zidovudine transport within the rabbit brain during intracerebroventricular administration and the effect of probenecid. , 1997, Journal of pharmaceutical sciences.

[21]  L. Li,et al.  Rapid-onset intranasal delivery of anticonvulsants: pharmacokinetic and pharmacodynamic evaluation in rabbits. , 2000, International journal of pharmaceutics.

[22]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[23]  T. Maurer,et al.  Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery , 2002, Biopharmaceutics & drug disposition.

[24]  Meihua Tu,et al.  Development of a computational approach to predict blood-brain barrier permeability. , 2004, Drug metabolism and disposition: the biological fate of chemicals.

[25]  K. Pettigrew,et al.  Drug entry into the brain , 1979, Brain Research.

[26]  S. Rapoport,et al.  An in situ brain perfusion technique to study cerebrovascular transport in the rat. , 1984, The American journal of physiology.

[27]  J. Polli,et al.  Rational use of in vitro P-glycoprotein assays in drug discovery. , 2001, The Journal of pharmacology and experimental therapeutics.

[28]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[29]  P. L. Golden,et al.  Blood-brain barrier efflux transport. , 2003, Journal of pharmaceutical sciences.

[30]  G Levy,et al.  Rapid Development of Functional Tolerance to Caffeine-Induced Seizures in Rats , 1988, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[31]  Cuiping Chen,et al.  P-glycoprotein limits the brain penetration of nonsedating but not sedating H1-antagonists. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[32]  B. Brodie,et al.  THE IMPORTANCE OF DISSOCIATION CONSTANT AND LIPID-SOLUBILITY IN INFLUENCING THE PASSAGE OF DRUGS INTO THE CEREBROSPINAL FLUID , 1960 .

[33]  Li Di,et al.  High throughput artificial membrane permeability assay for blood-brain barrier. , 2003, European journal of medicinal chemistry.

[34]  Roger L. Black,et al.  Goodman and Gilman's The Pharmacological Basis of Therapeutics , 1991 .

[35]  E. Jonsson,et al.  Morphine Blood-Brain Barrier Transport Is Influenced by Probenecid Co-Administration , 2003, Pharmaceutical Research.